Marom Edith M, Erasmus Jeremy J, Herndon James E, Zhang Chunfeng, McAdams H Page
Department of Radiology, Duke University Medical Center, Box 3808, Durham, NC 27710, USA.
AJR Am J Roentgenol. 2002 Jul;179(1):105-8. doi: 10.2214/ajr.179.1.1790105.
The purpose of our study was to assess the usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions and to assess the affect of ascites on the success rate of this treatment.
Twenty-five patients (mean age, 63 years) with metastatic gynecologic malignancies who had 26 symptomatic effusions treated at our institution over a 4-year period with imaging-guided catheter drainage and talc sclerotherapy were included in this study. Response to treatment was assessed by comparing pre-, immediate post-, and 30-day postsclerotherapy chest radiographs. Response to the treatment was graded as complete (no reaccumulation), partial (accumulation above immediate post- but below presclerotherapy level), or no response (reaccumulation to or above the presclerotherapy level). The presence of ascites on CT (n = 23), sonography (n = 1), direct intraoperative visualization (n = 1), or at physical examination (n = 1) was also noted.
Of the 25 patients, 13 patients with 14 treated malignant effusions survived at least 30 days after sclerotherapy and formed the final study group. The remaining patients either died (n = 11) or were lost to follow-up (n = 1). At 30 days, 12 of the 14 treated effusions showed complete responses and one showed a partial response. The overall response rate was 86%. Abdominal ascites was present at the time of treatment in 11 patients (79%) and did not affect the success rate (p > 0.999).
Imaging-guided catheter drainage and talc sclerotherapy are an effective treatment for symptomatic pleural effusions in patients with metastatic gynecologic malignancies. Ascites does not adversely affect the response to pleurodesis.
我们研究的目的是评估影像引导下导管引流及滑石粉硬化疗法在转移性妇科恶性肿瘤伴症状性胸腔积液患者中的有效性,并评估腹水对该治疗成功率的影响。
本研究纳入了25例(平均年龄63岁)转移性妇科恶性肿瘤患者,这些患者在4年期间于我院接受了影像引导下导管引流及滑石粉硬化疗法治疗,共有26例症状性胸腔积液。通过比较硬化疗法前、硬化疗法后即刻及硬化疗法后30天的胸部X光片评估治疗反应。治疗反应分为完全缓解(无再积聚)、部分缓解(积聚量高于硬化疗法后即刻但低于硬化疗法前水平)或无反应(再积聚至或高于硬化疗法前水平)。还记录了CT(n = 23)、超声(n = 1)、术中直接观察(n = 1)或体格检查(n = 1)时腹水的存在情况。
25例患者中,13例接受治疗的14例恶性胸腔积液患者在硬化疗法后至少存活30天,构成最终研究组。其余患者要么死亡(n = 11),要么失访(n = 1)。30天时,14例接受治疗的胸腔积液中有12例显示完全缓解,1例显示部分缓解。总体缓解率为86%。11例患者(79%)在治疗时存在腹水,腹水未影响成功率(p > 0.999)。
影像引导下导管引流及滑石粉硬化疗法是转移性妇科恶性肿瘤伴症状性胸腔积液患者的有效治疗方法。腹水不会对胸膜固定术的反应产生不利影响。